4-methyl-1-phenyl-1H-pyrazole-3-carboxylic acid | 241798-67-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-methyl-1-phenyl-1H-pyrazole-3-carboxylic acid
• 英文别名: 4-Methyl-1-phenyl-1H-pyrazol-3-carbonsaeure；4-methyl-1-phenylpyrazole-3-carboxylic acid
• CAS: 241798-67-4
• 化学式: C₁₁H₁₀N₂O₂
• mdl: MFCD24480178
• 分子量: 202.213
• InChiKey: LHRKEPMAEXHVOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-methyl-1-phenyl-1H-pyrazole-3-carboxylic acid 生成 1-苯基-4-甲基吡唑
  参考文献：
  名称：

  Birkinshaw; Oxford; Raistrick, Biochemical Journal, 1936, vol. 30, p. 407

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(4-甲基-1-苯基-1H-吡唑-3-基)-乙酮 在 甲醇 、 sodium hypoiodite 作用下， 生成 4-methyl-1-phenyl-1H-pyrazole-3-carboxylic acid
  参考文献：
  名称：

  Birkinshaw; Oxford; Raistrick, Biochemical Journal, 1936, vol. 30, p. 407

  摘要：

  DOI：

文献信息

• HETEROCYCLIC INHIBITORS OF MCT4
  申请人：Vettore, LLC

  公开号：US20180162822A1

  公开（公告）日：2018-06-14

  Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

  本文披露了一些化合物和组合物，适用于治疗由MCT4介导的疾病，如增殖性和炎症性疾病，其结构如下所示： 还提供了在人类或动物主体中抑制MCT4活性的方法。
• Novel acyl coenzyme A (CoA): Diacylglycerol acyltransferase-1 inhibitors: Synthesis and biological activities of diacylethylenediamine derivatives
  作者：Yoshihisa Nakada、Thomas D. Aicher、Yvan Le Huerou、Timothy Turner、Scott A. Pratt、Stephen S. Gonzales、Steve A. Boyd、Hiroshi Miki、Toshihiro Yamamoto、Hiroshi Yamaguchi、Koki Kato、Shuji Kitamura

  DOI：10.1016/j.bmc.2010.01.067

  日期：2010.4

  A series of diacylethylenediamine derivatives were synthesized and evaluated for their inhibitory activity against DGAT-1 and pharmacokinetic profile to discover new small molecule DGAT-1 inhibitors. Among the compounds, N-[2-([1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl}amino)ethyl]-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide 3x showed potent inhibitory activity and excellent PK profile

  合成了一系列二酰基乙二胺衍生物，并评估了其对DGAT-1的抑制活性和药代动力学，以发现新的小分子DGAT-1抑制剂。在化合物中，N- [2-（[1-苯基-3-（三氟甲基）-1 H-吡唑-4-基]羰基}氨基）乙基] -6-（2,2,2-三氟乙氧基）吡啶-3-羧酰胺3x显示出强大的抑制活性和出色的PK曲线。饮食引起的肥胖症小鼠口服3倍导致体重增加减少和白色脂肪组织重量减少。
• USE OF 4-SUBSTITUTED 1-PHENYLPYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGENTS AGAINST ABIOTIC PLANT STRESS
  申请人：BAYER INTELLECTUAL PROPERTY GMBH

  公开号：US20140329684A1

  公开（公告）日：2014-11-06

  The invention relates to the use of 4-substituted 1-phenylpyrazole-3-carboxylic acid derivatives of the general formula (I), or salts thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, for enhancing stress tolerance in plants to abiotic stress, for strengthening plant growth and/or for increasing plant yield, and to selected processes for preparing the compounds mentioned above.

  本发明涉及使用4-取代的1-苯基吡唑-3-羧酸衍生物（I）或其盐，其中一般式（I）中的基团对应于描述中给出的定义，用于增强植物对非生物胁迫的耐受性，加强植物生长和/或增加植物产量，并涉及选定的制备上述化合物的过程。
• N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia
  申请人：Pfizer Inc.

  公开号：US20030149043A1

  公开（公告）日：2003-08-07

  NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.

  NHE-1抑制剂，使用这种NHE-1抑制剂的方法以及含有这种NHE-1抑制剂的制药组合物。NHE-1抑制剂对于减少组织缺血引起的组织损伤是有用的。
• Amide Compounds
  申请人：Kitamura Shuji

  公开号：US20090286791A1

  公开（公告）日：2009-11-19

  The present invention provides compounds represented by the formula (Ia): the formula (Ib): the formula (Ic): and the formula (Id): wherein each symbol is as defined in the specification. According to the present invention, these compounds have a DGAT inhibitory activity and are useful for the prophylaxis, treatment or improvement of diseases or pathologies caused by high expression or high activation of DGAT.

  本发明提供的化合物由以下公式(Ia)、(Ib)、(Ic)和(Id)表示，其中每个符号如规范中所定义。根据本发明，这些化合物具有DGAT抑制活性，并且对于预防、治疗或改善由高表达或高活性的DGAT引起的疾病或病理状况是有用的。